SK Plasma landed a strategic investment from Indonesia’s sovereign wealth fund to build the country’s first plasma fractionation facility, marking a milestone in the Southeast Asian nation’s push for medical self-sufficiency.
The Indonesia Investment Authority will become the second-largest shareholder in PT SKPLASMA CORE INDONESIA, the local venture established by the South Korean pharmaceutical firm. The financial terms weren’t disclosed.
The plant, set to open in late 2026 in Karawang International Industrial City, will process up to 600,000 liters of plasma annually to produce critical blood products like albumin and immunoglobulin. Indonesia currently imports all its plasma-derived medicines.
To bridge supply during construction, SK Plasma will manufacture products at its Andong facility in South Korea using Indonesian plasma as raw material. The company, a unit of SK Chemicals, will also train local workers to ensure smooth operations once the plant launches.
INA CEO Ridha Wirakusumah said the project would strengthen Indonesia’s healthcare sovereignty through technology transfer. For SK Plasma, this marks its first partnership with Indonesia’s state investment fund, validating its technical expertise in plasma processing.
